Definitive Contract 75F40123C00192
Award Date
9/26/23
Potential Completion Date
9/29/26
Potential Value
$1.2M
Federal Agency
Food and Drug Administration
Awardee
Akina, Inc.
Ultimate Awardee
Not listed
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Lafayette, IN, USA
Solicitation Procedures
Two Step
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a definitive, firm-fixed-price contract awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services (HHS), to Akina, Inc., a minority-owned, for-profit, Asian-Pacific American manufacturer of research products and services. The $548,834 contract is for the development of advanced analytical techniques for mixed polymer drug-delivery systems, supporting the FDA's regulatory science and innovation goals. This contract, which has...
This is a definitive contract awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Akina, Inc., a minority-owned, for-profit Asian-Pacific American manufacturer, for the development of "NEW ANALYTICAL METHODS FOR COMPLEX SAMENESS OF INJECTABLE, LONG-ACTING PLGA FORMULATIONS" under Broad Agency Announcement (BAA) PMQWP#187. The contract, with a firm fixed price of $992,304.63, was awarded on September 25, 2019, and has a completion date of...
This is a $208,489 firm-fixed-price definitive contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to Akina, Inc., a minority-owned, for-profit, Asian-Pacific American manufacturer based in West Lafayette, Indiana. The contract has a total small business set-aside designation and a performance period ending on June 15, 2015. The contract supports the development of new analytical methods for complex long-acting injectable formulations,...
This $291,618 definitive contract was awarded by the Food and Drug Administration (FDA) to the Institute For Clinical Pharmacodynamics, Inc. (ICPI), a for-profit, minority-owned organization. The contract is in support of the FDA's Combatting Antibiotic Resistant Bacteria (CARB) program and will have a period of performance through September 29, 2023. Under this contract, ICPI will provide pharmacometric analysis and modeling services to the FDA to support updating clinical breakpoints for the...
This federal contract award was made by the Food and Drug Administration (FDA), a civilian agency, to Qrono, Inc., a for-profit company specializing in medical and scientific research and development. The $694,584.58 cost-plus-fixed-fee contract, titled "Computational Drug Delivery: Leveraging Predictive Models to Develop Bioequivalent Generic Long-Acting Injections," is focused on developing innovative drug delivery systems and immunotherapy approaches. The contract has an ultimate...
Landrau Scientific Innovations LLC was awarded a $567,980 firm fixed price definitive contract by the Department of Health and Human Services Food and Drug Administration to support the agency's Broad Agency Announcement PMQWP#237. This BAA seeks advanced research and development proposals to evaluate critical process parameters for the preparation of amphotericin B that influence toxicity, advancing the FDA's regulatory science and innovation goals. The prime contractor will conduct work at its...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Lakepharma, Inc., a minority-owned, for-profit Contract Development and Manufacturing Organization (CDMO). The $12,999 contract is for DNA scale-up services sufficient for 0.5L production to support the agency's medical research and healthcare mission. The contract has no set-aside designation and was awarded on September 2, 2020 with an...
This is a $355,941 firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Pion Inc., a for-profit manufacturer of scientific instrumentation and testing services based in Billerica, Massachusetts. The contract is for the delivery of a "Biorelevant Characterization System for Subcutaneous Formulations" to support the FDA's research and development efforts. The contract does not have a set-aside designation. Pion Inc. has previously secured multiple...
This is a new task order awarded under an existing Indefinite Delivery Indefinite Quantity (IDIQ) contract (HHSF223201610004I) with the Department of Health and Human Services Food and Drug Administration (FDA). The task order, valued at $2,470,791.00, is for a Pharmacokinetic (PK) study of opioid drug products following oral ingestion of chewed products. The study falls under the FDA's In Vivo Study of Generic Drug Products in Human Subjects program. The contract is a Firm Fixed Price...
This is a $5,545.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Lakepharma, Inc., a minority-owned and Asian-Pacific American-owned for-profit organization. The contract is for custom antibody and protein purification services to be performed in Belmont, CA. Lakepharma, Inc. is a contract development and manufacturing organization (CDMO) that has previously...